mTOR inhibition induces compensatory, therapeutically targetable MEK activation in renal cell carcinoma.

by Sean T Bailey, Bing Zhou, Jeffrey S Damrauer, Bhavani Krishnan, Harper L Wilson, Aleisha M Smith, Mingqing Li, Jen Jen Yeh, William Y Kim
Published 2014-01-01

Prevalence of DNA Repair Gene Mutations in Blood and Tumor Tissue and Impact on Prognosis and Treatment in HNSCC

by Kimberly M. Burcher, Andrew T. Faucheux, Jeffrey W. Lantz, Harper L. Wilson, Arianne Abreu, Kiarash Salafian, Manisha J. Patel, Alexander H. Song, Robin M. Petro, Thomas Lycan, Cristina M. Furdui, Umit Topaloglu, Ralph B. D’Agostino, Wei Zhang, Mercedes Porosnicu
Published 2021-06-01

MYC activation cooperates with Vhl and Ink4a/Arf loss to induce clear cell renal cell carcinoma

by Sean T. Bailey, Aleisha M. Smith, Jordan Kardos, Sara E. Wobker, Harper L. Wilson, Bhavani Krishnan, Ryoichi Saito, Hyo Jin Lee, Jing Zhang, Samuel C. Eaton, Lindsay A. Williams, Ujjawal Manocha, Dorien J. Peters, Xinchao Pan, Thomas J. Carroll, Dean W. Felsher, Vonn Walter, Qing Zhang, Joel S. Parker, Jen Jen Yeh, Richard A. Moffitt, Janet Y. Leung, William Y. Kim
Published 2017-06-01